Shire acquires SARcode Bioscience and Phase III lifitegrast for Dry Eye Disease
Shire plc will acquire SARcode Bioscience Inc., which brings a new phase III compound � Lifitegrast � currently under development for the signs and symptoms of Dry Eye Disease, into Shire�s portfolio. Shire anticipates launching lifitegradt in the United States as early as 2016 pending a positive outcome of the phase III clinical development program and regulatory approvals. Shire is acquiring the global rights to lifitegrast and will evaluate an appropriate regulatory filing strategy for markets outside of the United States.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.